

Kirin Invests in Food Technology Startup DAIZ Corporation - Maker of Miracle Meat - a Plant-Based Meat Made From Sprouted Soybeans

- Exploring initiatives to leverage advanced germination technology for foods -

TOKYO, April 19, 2021 – The KIRIN HEALTH INNOVATION FUND (KHIF), a corporate venture capital (CVC)¹ between Kirin Holdings Company, Ltd. (Kirin Holdings) and Global Brain Corporation (Global Brain) took a stake in DAIZ Corporation. (DAIZ) on March 31, 2021. DAIZ is a Kumamoto-based a food tech startup that develops and produces Miracle Meat, a plant-based meat ingredient made from germinated soybeans.

1. The practice of an operating company investing its corporate funds directly in an external startup company aligned with its business lines, intended to establish a mutually beneficial relationship or launch a new business by leveraging the latter's assets.

● About DAIZ Corporation

DAIZ Co., Ltd. is a food technology startup company that develops and produces Miracle Meat, a tasty and sustainable soy-based plant meat material that reproduces a taste and texture similar to meat and reduces the unusual flavor unique to soybeans, by combining the patented Ochiai High Pressure Method of germination with a unique manufacturing process. Through this investment, Kirin Holdings looks forward to DAIZ working with the Kirin Group to help provide tastier yet healthier food choices for our customers.

● What Makes “Miracle Meat” Different?

The "Ochiai High Pressure Method" patented germination technology, draws out the germination ability of plants from soybeans by controlling the growth conditions such as oxygen, carbon dioxide, temperature, and moisture, thereby increasing the nutritional value such as “umami” (amino acid).

By using high oleic soybeans as the raw material, the unique flavor of soybeans has been reduced.

By extruding the germinated soybeans, the meat-like texture is reproduced without the addition of other ingredients or additives.



Miracle Meat

● Purpose of Establishing the KIRIN HEALTH INNOVATION FUND

Through the KIRIN HEALTH INNOVATION FUND, Kirin Holdings intends to invest in startups around the globe that have innovative technologies and business models for resolving health issues, and to leverage their advanced health science technologies and solutions for improving customer experience. By combining the Kirin Group's wealth of assets and competence in health science with innovations and technologies that startups will bring to partnerships, Kirin Holdings will be better able to bolster its existing Food & Beverages domain as well as step up efforts to launch new businesses in its Health Science domain.



This further investment in health science is yet another development in achieving the goals in the *Kirin Group Vision 2027* (KV2027) plan. *Kirin Group Vision 2027* is the long-term management vision of the Kirin Group and sets out the broad goal of creating value across the world of Food & Beverages to Pharmaceuticals and

becoming a global leader in CSV². To augment the Group's existing Food & Beverages domain and Pharmaceuticals domain, the Group has launched a new Health Science domain to help people stay fit and healthy by leveraging advanced fermentation and biotechnology the Group has amassed over the years.

2. Creating Shared Value. Combined added value for consumers as well as for society at large.

Supplementary Information

(1) About the KIRIN HEALTH INNOVATION FUND

| | |
|-------------------------------|---|
| Fund name | KIRIN HEALTH INNOVATION FUND (registered as <i>KIRIN and GB Investment Limited Partnership</i>) |
| Primary sector for investment | Startups around the globe operating in the health science domain |
| Established | March 2020 |
| AUM | 5 billion yen |
| Investment period | 10 years |
| General partner | Global Brain Corporation |

(2) About Global Brain

| | |
|------------------|---|
| Company name | Global Brain Corporation |
| Head office | 10-11 Sakuragaokacho, Shibuya-ku, Tokyo, Japan |
| President | Yasuhiko Yurimoto |
| Established | January 1998 |
| Primary business | Venture capital business |
| URL | https://globalbrains.com/en |

(3) About DAIZ Corporation

| | |
|------------------|---|
| Company name | DAIZ Corporation |
| Head office | Terwell Kumamoto Building 7F, 1-1, Minami-Kumamoto 5-chome, Chuo-ku, Kumamoto City, Kumamoto Prefecture, Japan |
| President | Takeshi Ide |
| Established | December 1, 2015 |
| Primary business | Development, production and sales of soybean-derived vegetable meat ingredients (Miracle Meat) Development and production of food products using soybean-derived vegetable meat ingredients (Miracle Meat) |
| URL | https://www.daiz.inc/ |

About Kirin Holdings

Kirin Holdings Company, Limited is an international company that operates in the Food & Beverages domain (Food & Beverages businesses), Pharmaceuticals domain (Pharmaceuticals businesses), and Health Science domain (Health Science business), both in Japan and across the globe.

Kirin Holdings can trace its roots to **Japan Brewery** which was established in 1885. Japan Brewery became **Kirin Brewery** in 1907. Since then, the company expanded its business with fermentation and biotechnology as its core technologies, and entered the pharmaceutical business in the 1980s, all of which continue to be global growth centers. In 2007, Kirin Holdings was established as a pure holding company and is currently focusing on boosting its Health Science domain.

Under the [*Kirin Group Vision 2027*](#) (KV 2027), a long-term management plan launched in 2019, the Kirin Group aims to become “A global leader in CSV, creating value across our world of Food & Beverages to Pharmaceuticals.” Going forward, the Kirin Group will continue to leverage its strengths to create both social and economic value through its businesses, with the aim of achieving sustainable growth in corporate value.

###